MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
Clinical trials for MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS explained in plain language.
Never miss a new study
Get alerted when new MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS trials appear
Sign up with your email to follow new studies for MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to stop kidney disease from coming back after transplant
Disease control CompletedThis phase 2 study tested a drug called pegcetacoplan in 13 kidney transplant patients whose original kidney disease (C3G or IC-MPGN) had come back. The goal was to see if the drug could reduce signs of disease activity in the kidney. The study was small and early-stage, so resul…
Matched conditions: MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
Phase: PHASE2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Hope for rare kidney patients: new drug shows promise in phase 3 trial
Disease control CompletedThis study tested a drug called pegcetacoplan in 124 adults and teens with two rare kidney diseases (C3G and IC-MPGN). The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage. Participants received either the drug or a placebo twice a week for 2…
Matched conditions: MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC